XENE Investor Alert: Levi & Korsinsky Investigates Xenon Pharmaceuticals Inc. (XENE) for Potential Securities Fraud

By ACCESS Newswire

NEW YORK CITY, NY / ACCESS Newswire / September 22, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into Xenon Pharmaceuticals Inc. ("Xenon Pharmaceuticals Inc.") (NASDAQ:XENE) concerning potential violations of the federal securities laws.

Xenon Pharmaceuticals Inc. shares fell 30.17% on September 18, 2026, after the company temporarily paused new-patient enrollment in its Phase 3 trials of azetukalner for major depressive disorder and bipolar depression. The decision followed unexpected neuropsychiatric adverse events, including confusion, excessive drowsiness, coordination problems, and isolated psychotic episodes. Although epilepsy trials for the drug continue, the safety setback prompted analysts to downgrade the stock and cut price targets.

If you suffered a loss on your Xenon Pharmaceuticals Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171

SOURCE: Levi & Korsinsky, LLP



View the original press release on ACCESS Newswire

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.